Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc.'s clinical trials have shown promising results for its product candidate, Neflamapimod, particularly in treating dementia with Lewy bodies (DLB), demonstrating significant improvements in key biomarker endpoints such as plasma GFAP levels and the A42/40 ratio. The data indicates a strong correlation between biomarker changes and clinically meaningful outcomes, including lower dementia severity and an estimated 1.5-year extension in the time to clinical progression for patients without Alzheimer's co-pathology. With a favorable safety profile observed across extensive clinical exposure, this progress further supports the scientific basis for advancing to Phase 3 trials, positioning CervoMed favorably within the biotechnology sector focused on age-related neurologic disorders.

Bears say

CervoMed Inc faces several significant risks that contribute to a negative outlook on its stock, including potential delays in initiating a crucial Phase 3 trial for its product candidate, Neflamapimod, and the possibility of failing to generate positive data or secure regulatory approvals essential for its success in treating DLB. Additionally, there is concern regarding slower-than-expected market uptake of Neflamapimod, which could adversely impact revenue projections. The company's valuation methodology incorporates a high discount rate and a low probability of approval, reflecting cautious investor sentiment amid existing uncertainties.

CervoMed Inc (CRVO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.